DE69919754D1 - Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien - Google Patents

Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien

Info

Publication number
DE69919754D1
DE69919754D1 DE69919754T DE69919754T DE69919754D1 DE 69919754 D1 DE69919754 D1 DE 69919754D1 DE 69919754 T DE69919754 T DE 69919754T DE 69919754 T DE69919754 T DE 69919754T DE 69919754 D1 DE69919754 D1 DE 69919754D1
Authority
DE
Germany
Prior art keywords
negative bacteria
vaccine
gram negative
invaplex
purified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69919754T
Other languages
English (en)
Other versions
DE69919754T2 (de
Inventor
V Oaks
Ross Turbyfill
Berrong Hartman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter Reed Army Institute of Research
Original Assignee
Walter Reed Army Institute of Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27379338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69919754(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Walter Reed Army Institute of Research filed Critical Walter Reed Army Institute of Research
Application granted granted Critical
Publication of DE69919754D1 publication Critical patent/DE69919754D1/de
Publication of DE69919754T2 publication Critical patent/DE69919754T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/50—Lipopolysaccharides; LPS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69919754T 1998-09-30 1999-09-28 Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien Revoked DE69919754T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10239898P 1998-09-30 1998-09-30
US10239798P 1998-09-30 1998-09-30
US102398P 1998-09-30
US102397P 1998-09-30
US13619099P 1999-05-27 1999-05-27
US136190P 1999-05-27
PCT/US1999/022772 WO2000018355A2 (en) 1998-09-30 1999-09-28 Use of purified invaplex from gram negative bacteria as a vaccine

Publications (2)

Publication Number Publication Date
DE69919754D1 true DE69919754D1 (de) 2004-09-30
DE69919754T2 DE69919754T2 (de) 2005-09-01

Family

ID=27379338

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69919754T Revoked DE69919754T2 (de) 1998-09-30 1999-09-28 Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien

Country Status (6)

Country Link
US (4) US6245892B1 (de)
EP (1) EP1198245B1 (de)
AT (1) ATE274353T1 (de)
AU (2) AU1199900A (de)
DE (1) DE69919754T2 (de)
WO (2) WO2000018355A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2252438C (en) * 1996-04-19 2011-03-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
US7172762B1 (en) * 1999-01-29 2007-02-06 Pfizer Inc. Erysipelothrix rhusiopathiae antigens and vaccine compositions
GB0025058D0 (en) * 2000-10-12 2000-11-29 Smithkline Beecham Biolog Composition
JP4510382B2 (ja) * 2001-05-18 2010-07-21 ウォルター・リード・アーミー・インスティテュート・オヴ・リサーチ ゾンネ赤痢菌から得られるＩｎｖａｐｌｅｘ５０を含む組成物の使用、感染から保護し得る免疫応答を対象体において誘導するための組成物、ゾンネ赤痢菌から得られるＩｎｖａｐｌｅｘ５０を含むワクチン、ワクチンの使用、およびキット
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CA2506090A1 (en) * 2002-11-14 2004-05-27 Carmen Rosa Soto Rodriguez Method of obtaining conjugate vaccines and vaccine compositions containing same
EP2196210A1 (de) * 2003-10-24 2010-06-16 Nora, LLC Verfahren zur Reduzierung der Wahrscheinlichkeit von Präeklampsie bei einer Person, die darauf angewiesen ist
US20090226397A1 (en) * 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
CA2548202C (en) * 2003-11-25 2013-05-14 The Government Of The United States, As Represented By The Secretary Of The Army Use of shigella invaplex to transport functional proteins and transcriptionally active nucleic acids across mammalian cell membranes in vitro and in vivo
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US7833740B2 (en) * 2005-08-07 2010-11-16 Tgc Biomics Gmbh Test system for detecting salmonella
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
CA2563214A1 (en) * 2006-10-12 2008-04-12 Institut Pasteur Shigella ipad protein and its use as a potential vaccine against shigella infection
US7780966B2 (en) * 2007-03-27 2010-08-24 The United States Of America As Represented By The Secretary Of The Army Artificial invaplex
CN101711165B (zh) * 2007-03-27 2016-02-24 以沃尔特里德军事研究所的名义,由美国陆军部部长为代表的美国政府 人造侵袭素复合物
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
EP3246044B2 (de) * 2010-08-23 2024-04-10 Wyeth LLC Stabile formulierungen von neisseria-meningitidis-rlp2086-antigenen
ES2864635T3 (es) 2010-09-10 2021-10-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP3978013A3 (de) * 2012-09-06 2022-07-06 EveliQure Biotechnologies GmbH Neuartiger lebender abgeschwächter shigella-impfstoff
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
WO2015033251A2 (en) 2013-09-08 2015-03-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN112831487B (zh) * 2021-01-27 2022-05-06 武汉爱博泰克生物科技有限公司 一种重组蛋白酶k的纯化方法及其应用
CN113466321B (zh) * 2021-08-12 2022-10-14 河北省食品检验研究院 一种产志贺毒素大肠埃希氏菌的分型方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US5589380A (en) * 1992-06-05 1996-12-31 University Of Maryland At Baltimore Isolated DNA molecule encoding SHET1 of Shigella flexneri 2a and mutant Shigella flexneri 2a
US5679564A (en) * 1994-10-05 1997-10-21 Antex Biologics, Inc. Methods for producing enhanced antigenic campylobacter bacteria and vaccines
US5972899A (en) * 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
ATE331798T1 (de) * 1996-04-19 2006-07-15 Jackson H M Found Military Med Verfahren zur anregung einer immunantwort durch verabreichung von nutzorganismen, die intimin allein oder als fusionsprotein mit einem oder mehreren anderen antigenen exprimieren
US6342352B1 (en) * 1998-04-24 2002-01-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of detecting shigella and shigella mxiM DNA

Also Published As

Publication number Publication date
US20050013822A1 (en) 2005-01-20
US6680374B2 (en) 2004-01-20
WO2000018355A3 (en) 2000-11-23
EP1198245B1 (de) 2004-08-25
WO2000018354A2 (en) 2000-04-06
WO2000018355A2 (en) 2000-04-06
US6245892B1 (en) 2001-06-12
AU1098400A (en) 2000-04-17
US20010009957A1 (en) 2001-07-26
DE69919754T2 (de) 2005-09-01
EP1198245A2 (de) 2002-04-24
AU1199900A (en) 2000-04-17
WO2000018355A9 (en) 2001-08-16
ATE274353T1 (de) 2004-09-15
US6277379B1 (en) 2001-08-21
WO2000018354A3 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
ATE274353T1 (de) Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien
KR950700894A (ko) 탁솔 유도체(Taxol derivatives)
NZ618298A (en) A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
DE69731285D1 (de) Langwellig fluorezierende proteine
ATE211732T1 (de) N-benzylpiperidin- und tetrahydropyridin-derivate
DE69637844D1 (de) Neues tgf-beta-ahnliches cytokin
IT1293778B1 (it) 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
ES2143666T3 (es) P-amidinobencilamidas dipeptidicas con restos sulfonilo, o bien aminosulfonilo n-terminales.
ATE222930T1 (de) Antigene arznei zur behandlung oder vorbeugung
NO974322L (no) DNA som koder for human papillomvirus type 18
DK0840792T3 (da) (S)-hydroxynitrillyase fra Hevea brasiliensis
DK1395283T3 (da) Heterolog beskyttelse induceret ved immunisering med Invaplex-vaccine
DK0786004T3 (da) Kloning, ekspression og karakterisering af en hidtil ukendt form af phosphatidylinositol-3-kinase
DE59010919D1 (de) N- und O-substituierte Aminophenolderivate, Zwischenprodukte zu deren Herstellung, deren Verwendung als Hydrolasesubstrate, ein entsprechendes Bestimmungsverfahren und hierfür geeignetes diagnostisches Mittel
DE69728897D1 (de) Saeugetierchemokine
ATE92498T1 (de) Primycinkomponenten und verfahren zur trennung des antibiotischen komplexes.
TR199701298T1 (xx) Tetralinler.
ATE294237T1 (de) S?ugetier thymokingene
ATE185165T1 (de) Gen-expressionssystem
ATE376586T1 (de) Ppgpp-synthetase und expressionssysteme zur verbesserten herstellung von proteinen
DE60114608D1 (de) Verfahren zur herstellung von anthracyclinederivaten
ID28174A (id) Turunan 5-imino-13-deoksi antrasiklin, penggunaannya, dan proses pembuatannya
GB9502899D0 (en) Novel antigen
DE69104357D1 (de) Klonierungs- und/oder expressionsvektoren, verfahren zur ihrer herstellung und verwendung.
DE59905355D1 (de) Verwendung von katecholderivaten als proteinaseinhibitoren

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation